SecBot SecBot
PRESS-RELEASE ·Filed Sep 9, 2026

COO

CooperCompanies
MIXED
Impact 6/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The Q3 beat is overshadowed by CVI's flat revenue and a weak Q4 outlook for contact lenses. Watch for further channel destocking commentary on the call; the strategic review conclusion and expanded buyback provide a floor, but organic growth concerns at CVI cap upside. Monitor Q4 CVI revenue trajectory for signs of stabilization.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$54.17
T+0 close · Sep 9, 2026 · via day close
Latest settled
+0.24%
T+20 · $54.30 · next T+60 in 17d
Vs SPY
−1.88%
α at T+20
Latest observation
+16.40%
T+46 · FF3 residual α
  1. T+0 · Sep 10 $54.17entry
  2. T+1 · 2mo ago −0.48%α −1.33% · $53.91
  3. T+5 · 2mo ago −0.73%α −0.23% · $53.78
  4. T+20 · 6w ago +0.24%α −1.88% · $54.30
  5. T+47 · todayOpen
  6. T+60 · in 17d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CooperCompanies reported fiscal Q3 2026 non-GAAP EPS of $1.15, a 2.7% beat vs consensus of $1.12, on revenue of $1.066B (1% YoY growth, in line with $1.10B consensus). However, CooperVision revenue was flat YoY at $717M, and Q4 guidance for CVI organic growth of -2% to 0% signals continued channel inventory headwinds. The company completed its strategic review, expanded its buyback authorization to $3B, and repurchased $339M in stock, but the core contact lens business remains under pressure, making this a mixed read-through for the stock.

Key Financial Metrics

EPS
$1.15
est $1.12 · +2.7%
Revenue
$1.1B
est $1.1B · -3.1% · +0.6% YoY
Rating
in line
Guidance
$4.229B-$4.252B
maintained
Free Cash Flow
$273.0M
Gross Margin
67%

Key Facts

  • Non-GAAP EPS of $1.15 beat consensus of $1.12 by 2.7%
  • Revenue of $1.066B was slightly below the $1.10B consensus estimate
  • CooperVision revenue flat YoY at $717M; Q4 guidance calls for -2% to 0% organic growth
  • CooperSurgical revenue grew 2% to $349.2M, with fertility up 5% organically
  • Free cash flow rose 66% to $273.0M; $339.1M in stock repurchased during the quarter
  • Board expanded buyback authorization from $2B to $3B, with ~$1.5B remaining
  • Fiscal 2026 non-GAAP EPS guidance set at $4.51-$4.55; Q4 guidance $1.05-$1.09
  • GAAP EPS of $2.24 included a $307.2M discrete tax benefit from UK HMRC examination

Financial Impact

Non-GAAP EPS beat by $0.03 (2.7%) vs consensus; revenue miss of ~$34M (3.1%) vs consensus; Q4 CVI guidance implies -2% to 0% organic decline

revenueepsfree cash flowshare repurchasesguidance

Risk Factors

  • CooperVision organic revenue declining -2% to 0% in Q4, indicating prolonged channel inventory destocking
  • Total revenue guidance of $4.229-$4.252B implies Q4 revenue below consensus expectations
  • Non-GAAP EPS guidance of $4.51-$4.55 for FY2026 suggests Q4 EPS of $1.05-$1.09, below the $1.11 Street estimate for the next quarter
  • Flat CVI revenue in Q3 and negative Q4 guidance may signal market share loss or demand softness

Market Snapshot

Exchange
Nasdaq
Sector
Ophthalmic Goods
Analyst Consensus
57% bullish (23 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3359075

Track record

10 reports on COO

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +7.83% at T+20 after the Jun 4, 2026 report. 2 of 6 went positive at some point.

Filters
  1. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $59.41 Now $61.88 −4.16% settles Nov 25
  2. Oct 15, 20264w ago Institutional Cluster Bearish 4/10 Entry $57.40 to $62.93 Now $61.88 −7.80% ▼ −9.63% −11.05% vs SPY
  3. Sep 17, 20268w ago Insider Cluster Bullish 4/10 Entry $55.29 to $57.94 Now $61.88 +11.92% ▲ +4.79% +4.59% vs SPY
  4. Sep 15, 20268w ago Insider Cluster Neutral 2/10 Entry $54.61 to $54.88 Now $61.88 +13.31% ▲ +0.49% −1.57% vs SPY
  5. Sep 9, 20269w ago Press Release Mixed 6/10 Viewing Entry $54.17 to $54.30 Now $61.88 +14.23% ▲ +0.24% −1.88% vs SPY
  6. Jun 4, 202623w ago 8-K Mixed 6/10 No price data
  7. Jun 4, 202623w ago Press Release Bullish 6/10 Entry $67.34 to $72.61 Now $61.88 −8.11% ▲ +7.83% +5.96% vs SPY
  8. Mar 5, 202636w ago 8-K Bullish 8/10 Entry $76.36 to $70.15 Now $61.88 −18.97% ▼ −8.13% −6.09% vs SPY
  9. Mar 5, 202636w ago Press Release Bullish 8/10 Entry $76.36 to $70.15 Now $61.88 −18.97% ▼ −8.13% −6.09% vs SPY
  10. Feb 24, 202637w ago DEFA14A Neutral 2/10 Entry $83.38 to $71.35 Now $61.88 −25.79% ▼ −14.43% −9.19% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens Wed (11h 44m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026